Latest Content

PARADIGM showed azacitidine and venetoclax outperform induction chemotherapy in initial treatment of acute myeloid leukemia (AML).

SABCS 2025 will spotlight new advances in breast cancer research while offering networking opportunities to foster connections among attendees.

Epcoritamab combined with rituximab and lenalidomide significantly improves outcomes for relapsed follicular lymphoma, setting a new treatment standard.

Updated results highlight the promise of epcoritamab combined with chemotherapy for newly diagnosed DLBCL.

A panel at the American Society of Hematology highlights the urgent need for genetic diversity in cancer studies, addressing disparities in treatment outcomes across different ancestries.

Families of children with acute lymphoblastic leukemia face significant financial toxicity, with many experiencing severe economic hardship during treatment.

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.

A phase 2 trial demonstrated substantial weight loss with the long-acting peptide–antibody conjugate, as well as other cardiometabolic improvements.

Rusfertide shows promise in maintaining hematocrit control and improving quality of life for polycythemia vera patients, reducing phlebotomy needs significantly.